What a hemodialysis study of semaglutide versus dulaglutide or liraglutide reported
A large observational study using U.S. Renal Data System and Medicare records compared semaglutide against two other GLP-1 medications in people with diabetes on maintenance hemodialysis. It reported differences in mortality, hospitalization, and body weight, but it is not a randomized trial and applies to a specific patient group.
Researchers published a study in Diabetes Care that asked a practical question. Among people with diabetes who are on maintenance hemodialysis, does one GLP-1 medication appear to perform differently from others?
This was done in humans, not in animals or cells. But it was not a conventional randomized trial. The team used existing medical records from 2011 to 2022 and applied statistical methods to imitate what a trial might have measured. That approach is called a target trial emulation.
What the researchers studied
They drew on the U.S. Renal Data System and Medicare data to find patients receiving hemodialysis who were taking a GLP-1 medication. They identified 1,312 people using semaglutide and 2,601 using either dulaglutide or liraglutide.
To make the groups more comparable, they used a statistical technique called overlap weighting to adjust for differences between patients. After weighting, the effective sample was 3,200 people. The median follow-up was about 1.1 years. The group had a mean age of 61, was 52% male, and had a median BMI of 34.
What they reported
Compared with dulaglutide or liraglutide, semaglutide was associated with a lower rate of death on dialysis. The one-year cumulative incidence was 11% versus 13%, with a subdistribution hazard ratio of 0.82.
Semaglutide was also associated with slightly fewer all-cause hospitalizations. The one-year incidence was 57% versus 62%. Body weight loss at one year was greater with semaglutide, reported as -4.8% versus -3.4%.
The details matter when you separate the comparison medications. Against dulaglutide specifically, semaglutide showed similar benefits for mortality and hospitalization. Against liraglutide, the authors reported no statistically significant benefit for either outcome.
What this does and does not establish
This study describes associations in a specific population: people with diabetes who are on maintenance hemodialysis. It does not establish that semaglutide will produce any particular result for an individual, and it does not speak to people who are not on dialysis. Outcomes vary from person to person.
An association is not the same as proof of cause. Because patients were not randomly assigned to their medications, unmeasured differences between the groups could still influence the results, even after statistical adjustment. The authors themselves framed the conclusion cautiously, noting semaglutide may be preferred over dulaglutide where there is clinical equipoise.
One honest limitation
The study was observational and built from insurance and registry records rather than a controlled trial. That design cannot rule out confounding the way random assignment can, and the follow-up was relatively short at roughly one year. The findings are a reasonable signal, not a final verdict.
If you are considering care
GLP-1 medications are prescription treatments, and decisions about them depend on your full medical picture, including kidney function. This article is general information, not medical advice. A licensed clinician should weigh whether any medication fits your situation.
Live Vital offers physician-prescribed semaglutide through a telehealth practice where protocols are reviewed by Dr. Patrick Taylor, MD. Any treatment requires a medical intake and physician approval, which you can begin at get started, and a prescription is never guaranteed. Live Vital does not accept insurance, though HSA and FSA funds are generally eligible.